Clinical Trials
- A 48-week, 6-arm, randomized, double-blind, placebo-controlled multicenter trial to assess the safety and efficacy of multiple CFZ533 doses administered subcutaneously in two distinct populations of patients with Sjögren’s Syndrome (TWINSS) (Enrollment Complete)
- A phase 2 randomized, double-blind, placebo-controlled, proof of concept study to evaluate the efficacy and safety of VIB4920 in subjects with Sjögren’s syndrome (SS) (Enrollment Complete)
- A randomized, double-blind, placebo controlled, multicenter phase III study to assess the efficacy and safety of ianalumab in patients with active Sjögren’s syndrome (NEPTUNUS) (Coming Soon)
Other Research Studies
Longitudinal Study of a Prospective Cohort of Patients with Sjögren’s Syndrome
Dr. Alan Baer has established a Sjögren’s syndrome cohort in the Jerome L. Greene Sjögren’s Syndrome Center. Information is being collected about the clinical history and long-term disease progression of patients with suspected or established Sjögren’s syndrome. Questionnaires, sera and salivary glands are collected upon entry into the study. Questionnaires are distributed electronically every 3 months and sera is collected bi-annually and stored for future studies. This cohort consists of over one thousand participants and continues to grow.
Sjögren’s Syndrome Screening Dry Eye Study (SSDE Study)
- PI: Dr. Alan Baer
- Co-Investigator: Dr. Esen Akpek
Sjögren’s syndrome is a systemic autoimmune disorder characterized by lymphocytic infiltration of the salivary and lacrimal glands and other organs along with systemic production of autoantibodies. The involvement of salivary and lacrimal glands leads to progressive decreases in the quantity and quality of saliva and tears and impaired quality of life. Local treatment of the dry eyes and mouth can prevent complications, but does not appear to alter the course of the disease. Early diagnosis and implementation are critical in improving patients’ quality of life and treating complications.
Patients often first present to ophthalmologist with complaints of dry eye, and as a result ophthalmologists are in a unique position to screen patients for possible Sjögren’s syndrome. However, currently there are no evidence-based screening tools for ophthalmologists to use to identify patients with a high likelihood of having Sjögren’s syndrome. The central hypothesis of this research is that using a screening algorithm comprised of a combination of questionnaire responses, autoantibody tests and standard dry eye exam findings will stratify dry eye patients into those having high, medium or low likelihood of having Sjögren’s syndrome.
